A randomized, double-blind, placebo-controlled trial of testosterone for treatment of postmenopausal women with aromatase inhibitor-induced arthralgias: Alliance study A221102-Reference-Cited by-同舟云学术

A randomized, double-blind, placebo-controlled trial of testosterone for treatment of postmenopausal women with aromatase inhibitor-induced arthralgias: Alliance study A221102

Published:2020-05-06 Issue:1 Volume:29 Page:387-396
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Cathcart-Rake Elizabeth,Novotny Paul,Leon-Ferre Roberto,Le-Rademacher Jennifer,Storrick Elizabeth M.,Adjei Araba A.,Terstriep Shelby,Glaser Rebecca,Giuliano Armando,Mitchell William R.,Page Seth,Austin Colleen,Deming Richard L.,Ferreira Margaret A.,Lafky Jacqueline M.,Birrell Stephen N.,Loprinzi Charles L.

Funder

National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00520-020-05473-2.pdf

Reference49 articles.

1. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T, ATAC Trialists’ Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359(9324):2131–2139

2. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS, ATAC Trialists’ Group (2005) Results of the ATAC (Arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365(9453):60–62

3. Harris PF, Remington PL, Trentham-Dietz A, Allen CI, Newcomb PA (2002) Prevalence and treatment of menopausal symptoms among breast cancer survivors. J Pain Symptom Manag 23(6):501–509